January 21, 2021

Mivi Neuroscience Secures Series B Funding

January 21, 2021—Mivi Neuroscience, a medical device company focused on treatment of ischemic stroke, announced the closing of its Series B funding.

According to the company, the investment will be used to fund the clinical trials and subsequent commercialization of Mivi’s Q aspiration system and DAISe thrombectomy system. Additionally, the funds will help expand the company’s commercial operations outside the United States and support the development of several devices designed to support and enhance the company’s products.

The funding, which includes $35 million in new money plus the conversion of previously issued convertible notes, was led by a major multinational med-tech company with participation from new investors Perceptive Advisors, Deerfield Management, and Aphelion/Cardeation Capital, as well as existing investors including Concord Health Partners.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

January 21, 2021

Mivi Neuroscience Secures Series B Funding

Current Issue

Keep In Touch